Cancer chemotherapy : challenges for the future : proceedings of the Seventh Nagoya International Symposium on Cancer Treatment, Nagoya, Japan, September 29-30, 1991
著者
書誌事項
Cancer chemotherapy : challenges for the future : proceedings of the Seventh Nagoya International Symposium on Cancer Treatment, Nagoya, Japan, September 29-30, 1991
（International congress series, no. 1022）
Excerpta Medica, 1992
- v. 7
大学図書館所蔵 件 / 全12件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographies and index
内容説明・目次
内容説明
In the past six volumes of the proceedings of this symposium, many problems of cancer chemotherapy have been reported and discussed from the viewpoint of clinical and basic studies. At this symposium the main topics were new strategies for cancer therapy based on biology and pharmacology. Over 500 oncologists attended this meeting. In addition to the keynote address, presentations on the biology of tumour progression and regression covered the molecular basis of cancer suppression by the human tumour suppressor genes, mutation of the p53 gene and accumulation of the p53 protein, tumour suppressor genes involved in the pathogenesis of lung cancer and lessons learned from studies on tumour suppression by chromosome transfer. Many new reports on oncogenes provided the highlights for those chemotherapists present. For cancer therapy based on pharmacology, papers were presented on drug resistance such as P-glycoprotein (p170) multidrug resistance (MDR) transporter limitations on successful therapy for childhood tumours: possible circumvention of MDR by cyclosporin A, regulation of the MDR gene in response to environmental stimuli, and dose-intensive chemotherapies.
On the subject of cancer therapies, lung cancer was the focus of attention, and the efficacy of combined modalities was reported and discussed. This publication should provide new concepts and important information for developing cancer chemotherapy to many oncologists working in both clinical and basic research.
目次
- New strategies for the management of ovarian and breast cancer based on biology and pharmacology, R.C. Bast Jr et al. Part 1 Biology of tumour progression and regression - recessive oncogenes: molecular basis of cancer suppression by the human tumour suppressor genes, W.-H. Lee et al
- mutation of the p53 gene and accumulation of the p53 protein - common steps in human cancer that provide novel targets for chemotherapy, D.P. Lane
- tumour suppressor genes involved in the pathogenesis of lung cancer, T. Takahashi
- studies on tumour suppression by microcell-mediated chromosome transfer, M. Oshimura and A. Kurimasa. Part 2 Oncogenes molecular pathogenesis of non-Hodgkin lymphoma, G. Gaidano et al
- role of Src-like proto-oncogenes in lymphocyte signalling, T. Yamamoto
- suppression of cell-cell adhesion by v-src transformation - a molecular base of tumour invasion and metastasis, M. Hamaguchi. Part 3 Cancer therapy based on pharmacology - drug resistance: the P-glycoprotein multidrug resistance transporter limits successful therapy of childhood tumours - possible circumvention by chemosensitizers, H.S.L. Chan et al
- circumvention of multidrug resistance (MDR) and regulation of the MDR gene in response to environmental stimuli, M. Kuwano and K. Kohno. Part 4 Dose intensity: dose intensity - retrospective reviews and prospective trials, W.M. Hryniuk
- epirubicin in lung cancer, M.E. Blackstein and R. Feld
- dose intensive chemotherapy for lung cancer, M. Kawahara et al. Part 5 Cancer therapy based on biology: biological basis for modifying radiotherapy and chemotherapy, H.R. Withers. Part 6 Combined modalities for lung cancer - chemoradiation: combined chemotherapy and radiotherapy in the treatment of lung cancer, M. Wolf
- combined modality treatment of chemotherapy and thoracic radiotherapy for limited-stage small cell lung cancer, T. Tamura
- chemotherapy combined with interferons in lung cancer, K. Mattson. Part 7 Neoadjuvant chemotherapy: neoadjuvant chemotherapy in non-small cell lung cancer, N. Martini and M.G. Kris
- neoadjuvant therapy for non-small cell lung cancer, N. Hara et al. Part 8 Clinical trials based on pharmacology - pharmacokinetics and pharmacodynamics: the relevance of the investigation of clinical pharmacokinetics and pharmacodynamics in medical oncology, D.I. Jodrell and M.J. Egorin. Part 9 Administration methods of anticancer drugs: a pharmacokinetic hypothesis for the clinical efficacy of etoposide in small cell lung cancer (SCLC) and the activity of a prolonged schedule of etoposide in patients with SCLC, P.I. Clark
- combination of cisplatin and carboplatin in vitro and in clinical practice, K. Kobayashi et al
- individualized administration of anticancer drugs, M.V. Relling et al. Part 10 Special lecture: importance of pharmacokinetics for developing new therapies, F. Muggia et al.
「Nielsen BookData」 より